Bristol Myers acquires cell therapy partner 2seventy bio for about $286 million
Bristol Myers Squibb will acquire 2seventy bio for about $286 million in cash, sending the cancer cell therapy maker's shares ...
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating 2seventy bio, Inc. Buyout
Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities ...
Le Lézard23h
BC.GAME Team Compete for Top Prizes as BC.GAME ESPORTS Expands Its Line-Up
Global iGaming platform BC.GAME has announced plans to expand upon its first esports team led by a quintet of world-class ...
Bristol Myers to acquire cell therapy partner 2seventy bio in $286M all-cash deal
Abecma is being jointly developed and commercialized in the U.S. as part of a co-development, co-promotion, and profit share ...
Spotify upgraded, Freshpet downgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...
DelveInsight Business Research, LLP: BREYANZI Demonstrates Continued Growth in the Competitive CAR-T Market | DelveInsight
BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...
BREYANZI Demonstrates Continued Growth in the Competitive CAR-T Market | DelveInsight
DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR ...